Creating Growth Drivers through R&D Leadership
First written in FY2016. 26 of 36 entries say "Restated". Latest entry: FY2026.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Ajinomoto Group's R&D expenditure for the current consolidated fiscal year was ¥32,108 million. The Group held approximately 4,280 patents in Japan and overseas.」
R&D expenditure increased from ¥30.921 billion in the previous fiscal year to ¥32.108 billion, while patents held increased from approximately 4,200 to approximately 4,280. The company continues to invest in R&D aimed at achieving well-being by 2030 and advancing 4 growth areas. - 2026-05-07AdvancedRevision of earnings forecasts
「Research and development expenses △30,921 △32,108」
Research and development expenses increased from ¥30.921 billion in the previous fiscal year to ¥32.108 billion in the current fiscal year. - FY2026-H1RestatedAnnual report
「R&D expenditure for the group as a whole during the current interim consolidated period was ¥15.1 billion. There were no material changes in the status of the Group's R&D activities during the current interim consolidated period.」
The company disclosed interim R&D expenditure of ¥15.1 billion and reaffirmed that there were no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「The Ajinomoto Group's R&D expenditure for the current consolidated fiscal year was ¥30,921 million. The Group held approximately 4,200 patents in Japan and overseas.」
R&D expenditure increased from ¥28.766 billion in the previous fiscal year to ¥30.921 billion, and the company disclosed approximately 4,200 patents held. - FY2025-H1RestatedAnnual report
「R&D expenditure for the group as a whole during the current interim consolidated period was ¥14.7 billion. There were no material changes in the status of the Group's R&D activities during the current interim consolidated period.」
The company stated that there were no material changes in its R&D activities and disclosed interim R&D expenditure of ¥14.7 billion. - FY2024AdvancedAnnual report
「The Ajinomoto Group's R&D expenditure for the current consolidated fiscal year was ¥28,766 million. The Group held approximately 4,100 patents in Japan and overseas.」
The company increased R&D expenditure from ¥25.867 billion in the previous fiscal year to ¥28.766 billion and disclosed approximately 4,100 patents held. It also provided greater detail on the positioning of R&D linking AminoScience® with 4 growth areas. - FY2024-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥20.2 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed cumulative third-quarter R&D expenditure of ¥20.2 billion. - FY2024-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥13.8 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥13.8 billion for the cumulative second-quarter period. - FY2024-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥7.2 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed first-quarter R&D expenditure of ¥7.2 billion. - FY2023AdvancedAnnual report
「The Ajinomoto Group aims to become a company that contributes to the well-being of people, society and the planet through AminoScience® by 2030. AminoScience® is a collective term for the diverse materials, functions, technologies and services derived from research and commercialization processes that have focused rigorously on the functions of amino acids since the company's founding. The Ajinomoto Group's R&D expenditure for the current consolidated fiscal year was ¥25,867 million.」
The company linked R&D to achieving well-being through AminoScience® by 2030 and disclosed R&D expenditure of ¥25.867 billion, together with specific development activities in CDMO, electronic materials and culture media, among others. - FY2023-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥18.6 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥18.6 billion for the cumulative third quarter period. - FY2023-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥12.5 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥12.5 billion for the second quarter of the current consolidated cumulative period. - FY2023-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥6.5 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed first-quarter R&D expenditure of ¥6.5 billion. - FY2022AdvancedAnnual report
「The Ajinomoto Group aims to become a company that solves issues related to food and health. With respect to R&D, it has been reorganizing its structure since 2019 by role and function into organizations including the Bio & Fine Chemicals Research Institute, the Food Products Research Institute and the Information Planning Department, now the DX Promotion Department, as it transforms toward Agile R&D. In April 2021, the Group also consolidated the domestic food-related R&D sites of 3 group companies in cooperation with its consolidated subsidiaries 味の素冷凍食品㈱ and 味の素AGF㈱.」
The company is developing the reorganization toward Agile R&D and the consolidation of the 3 companies' domestic food R&D sites into R&D focused on Green, Food & Wellness, Healthcare and ICT, with a view to 2030 and 2050. - FY2022-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥17.9 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥17.9 billion for the third quarter of the current consolidated cumulative period. - FY2022-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥12.3 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥12.3 billion for the second quarter of the current consolidated cumulative period. - FY2022-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥6.3 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥6.3 billion for the first quarter of the current consolidated cumulative period. - FY2021AdvancedAnnual report
「In April 2021, the Group consolidated its domestic food-related R&D sites operated by 3 group companies in cooperation with its consolidated subsidiaries 味の素冷凍食品㈱ and 味の素AGF㈱.」
As part of the transformation to Agile R&D, following the reorganization of the research institutes in April 2019, the company consolidated the domestic food R&D sites of 味の素, 味の素冷凍食品 and 味の素AGF in April 2021. R&D expenditure was ¥25.9 billion. - FY2021-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥18.4 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed cumulative third-quarter R&D expenditure of ¥18.4 billion. - FY2021-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥12.3 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥12.3 billion for the second quarter of the current consolidated cumulative period. - FY2020AdvancedAnnual report
「Ajinomoto Co.,Inc.'s former Institute for Innovation Research, which had conducted R&D in new fields and provided technology support across the company, was reorganized in April 2019 by role and function into the Bio & Fine Chemicals Research Institute, the Food Products Research Institute, the Information Planning Department and other organizations, from the perspective of an R&D structure aligned with the business. Under the new R&D structure linked to the businesses launched, the Group aims to achieve sustainable growth and greater agility and speed in addressing customer issues by integrating the process from basic research through product development and industrialization.」
The company outlined an integrated R&D process spanning basic research through product development and industrialization following the reorganization of its research institutes in April 2019. R&D expenditure was ¥27.596 billion. - FY2020-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥20.1 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥20.1 billion for the cumulative third quarter period. - FY2020-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥13.8 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥13.8 billion for the second quarter of the current consolidated cumulative period. - FY2020-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥7.4 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed first-quarter R&D expenditure of ¥7.4 billion. - FY2019AdvancedAnnual report
「From fiscal 2019, the R&D structure will be reorganized to focus and shift resources to business areas with high growth potential, improve asset efficiency, increase productivity and accelerate product development. The Knorr Foods Co., Ltd. Development and Technology Center will be integrated into Ajinomoto Co.,Inc.'s Food Products Research Institute. At Ajinomoto Co.,Inc., the Institute for Innovation Research will be incorporated into the Food Products Research Institute, the Bio & Fine Chemicals Research Institute and other organizations, accelerating the creation of results and establishing a structure for R&D that can contribute rapidly to the business.」
In addition to the previous policy of investing ¥27.823 billion in R&D, the company moved from fiscal 2019 toward reorganizing its structure by integrating research institutes and development and technology centers to focus resources and accelerate the creation of results. - FY2019-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥20.1 billion. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥20.1 billion for the cumulative third quarter period. - FY2019-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥14.2 billion. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥14.2 billion for the second quarter of the current consolidated cumulative period. - FY2019-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥7.4 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed quarterly R&D expenditure of ¥7.4 billion. - FY2018-Q3RestatedAnnual report
「R&D expenditure for the group as a whole during the third quarter of the current consolidated cumulative period was ¥19,848 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥19,848 million for the third quarter of the current consolidated cumulative period. - FY2018-Q2RestatedAnnual report
「R&D expenditure for the group as a whole during the second quarter of the current consolidated cumulative period was ¥13,593 million. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥13,593 million for the second quarter of the current consolidated cumulative period. - FY2018-Q1RestatedAnnual report
「R&D expenditure for the group as a whole during the first quarter of the current consolidated cumulative period was ¥7,269 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in its R&D activities and disclosed R&D expenditure of ¥7,269 million for the quarter. - FY2017RestatedAnnual report
「To use technological capabilities to lead the “specialty” that other companies and existing offerings do not possess, we have positioned “R&D leadership” as a growth driver and are prioritizing investment in R&D resources in areas where our “world-leading seasoning technologies” and “proprietary advanced biotechnology” technologies, which are expected to deliver high growth, can be utilized.」
The company continued its policy of making R&D a growth driver and prioritizing R&D resources in seasoning technologies and advanced biotechnology. R&D expenses were ¥27.134 billion. - FY2017-Q3RestatedAnnual report
「We will further deepen the elucidation and design of “deliciousness” through our “world-leading seasoning technologies” and deliver it to more consumers. We will also leverage our “proprietary advanced biotechnology” to develop high-performance biobased materials, promote fermentation using fewer resources, and expand into areas including culture media for regenerative medicine and diagnostic businesses using AminoIndex technology, thereby driving growth.」
The company continued its R&D policy of making seasoning technologies and advanced biotechnology growth drivers. R&D activity expenses for the nine months ended 31 December were ¥19.968 billion, with no material changes in activity. - FY2017-Q2RestatedAnnual report
「We will further deepen the elucidation and design of “deliciousness” through our “world-leading seasoning technologies” and deliver it to more consumers. We will also leverage our “proprietary advanced biotechnology” to develop high-performance biobased materials, promote fermentation using fewer resources, and expand into areas including culture media for regenerative medicine and diagnostic businesses using AminoIndex technology, thereby driving growth.」
The company continued its R&D policy of making seasoning technologies and advanced biotechnology growth drivers. R&D activity expenses for the six months ended 30 September were ¥14.656 billion. - FY2017-Q1RestatedAnnual report
「We will further deepen the elucidation and design of “deliciousness” through our “world-leading seasoning technologies” and deliver it to more consumers. We will also leverage our “proprietary advanced biotechnology” to develop high-performance biobased materials, promote fermentation using fewer resources, and expand into areas including culture media for regenerative medicine and diagnostic businesses using AminoIndex technology, thereby driving growth. Group-wide R&D activity expenses for the three months ended 30 June were ¥7.188 billion.」
The company reiterated its policy of applying seasoning technologies and advanced biotechnology to growth areas and reported quarterly R&D expenses. There were no material changes in R&D activities. - FY2016First statedAnnual report
「We have positioned “R&D leadership” as a growth driver and are prioritizing investment in R&D resources in areas where our “world-leading seasoning technologies” and “proprietary advanced biotechnology” technologies, which are expected to deliver high growth, can be utilized.」
R&D resources were concentrated in seasoning technologies, advanced biotechnology, high-performance materials, regenerative medicine, diagnostics, and other areas. R&D expenses for the fiscal year were ¥32.594 billion.